Entasis Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
55
- Latest Deal Type
-
M&A
- Financing Rounds
-
11
Entasis Therapeutics General Information
Description
Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).
Contact Information
Website
www.entasistx.com(Operating Subsidiary)
Corporate Office
- Boston BioHub
- 35 Gatehouse Drive
- Waltham, MA 02451
- United States
Corporate Office
- Boston BioHub
- 35 Gatehouse Drive
- Waltham, MA 02451
- United States
Entasis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Entasis Therapeutics Comparisons
Industry
Financing
Details
Entasis Therapeutics Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Scynexis | Formerly VC-backed | Jersey City, NJ | ||||
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Xellia Pharmaceuticals | Private Equity-Backed | Copenhagen, Denmark | ||||
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ |
Entasis Therapeutics Patents
Entasis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3205756-A1 | Fixed dosage antibiotic compositions | Pending | 20-Jan-2021 | ||
| EP-4281042-A1 | Fixed dosage antibiotic compositions | Pending | 20-Jan-2021 | ||
| US-20230068309-A1 | Managing microbial dysbiosis with temocillin | Pending | 23-Dec-2019 | ||
| EP-4081214-A1 | Managing microbial dysbiosis with temocillin | Active | 23-Dec-2019 | ||
| CA-3162777-A1 | Managing microbial dysbiosis with temocillin | Pending | 23-Dec-2019 | A61K31/431 |
Entasis Therapeutics Executive Team (12)
| Name | Title | Board Seat |
|---|---|---|
| Manoussos Perros Ph.D | Founder & Chief Executive Officer & President | |
| John Mueller Ph.D | Chief Development Officer | |
| David Altarac | Chief Medical Officer |
Entasis Therapeutics Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | Board Member |
Entasis Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Entasis Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Entasis Therapeutics FAQs
-
When was Entasis Therapeutics founded?
Entasis Therapeutics was founded in 2015.
-
Who is the founder of Entasis Therapeutics?
Manoussos Perros Ph.D is the founder of Entasis Therapeutics.
-
Who is the CEO of Entasis Therapeutics?
Manoussos Perros Ph.D is the CEO of Entasis Therapeutics.
-
Where is Entasis Therapeutics headquartered?
Entasis Therapeutics is headquartered in Waltham, MA.
-
What is the size of Entasis Therapeutics?
Entasis Therapeutics has 55 total employees.
-
What industry is Entasis Therapeutics in?
Entasis Therapeutics’s primary industry is Pharmaceuticals.
-
Is Entasis Therapeutics a private or public company?
Entasis Therapeutics is a Private company.
-
What is the current valuation of Entasis Therapeutics?
The current valuation of Entasis Therapeutics is .
-
What is Entasis Therapeutics’s current revenue?
The current revenue for Entasis Therapeutics is .
-
How much funding has Entasis Therapeutics raised over time?
Entasis Therapeutics has raised $264M.
-
Who are Entasis Therapeutics’s investors?
AstraZeneca, CARB-X, Frazier Healthcare Partners, Novo Holdings, and Pivotal Life Sciences are 5 of 7 investors who have invested in Entasis Therapeutics.
-
Who are Entasis Therapeutics’s competitors?
Scynexis, Moderna, Spero Therapeutics, Xellia Pharmaceuticals, and Melinta Therapeutics are some of the 25 competitors of Entasis Therapeutics.
-
When was Entasis Therapeutics acquired?
Entasis Therapeutics was acquired on 11-Jul-2022.
-
Who acquired Entasis Therapeutics?
Entasis Therapeutics was acquired by Innoviva.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
